Pelabresib and Ruxolitinib Combination Proves Durable in Patients With MyelofibrosisAugust 21st 2022
Results from the MANIFEST study of pelabresib and ruxolitinib in myelfibrosis are positive. The phase MANIFEST-2 study continue to explored the combination in JAK inhibitor–naïve patients with myelofibrosis.
Momelotinib Shows Promise for the Future of Treating MyelofibrosisJuly 15th 2022
In an interview with Targeted Oncology, Aaron T. Gerds, MD, MS, discussed phase 3 MOMENTUM study and how it has impacted the clinical trial development of momelotinib for the treatment of patients with myelofibrosis.
Ruxolitinib Shows Superiority Over BAT in Second-Line, Inadequately-Controlled Polycythemia VeraJune 29th 2022
Five-year data from the RESPONSE-2 study combined with prior RESPONSE study results show that there is an option for the roughly 40% of patients with polycythemia vera who become intolerant or resistant to hydroxyurea.
Roundtable Discussion: Exploring Bone Marrow Biopsies, Prognostication, and Treatment in MyelofibrosisApril 20th 2022
During a Targeted Oncology case-based roundtable event, Srdan Verstovsek, MD, PhD, discussed the procedure of prognosis, biopsy, and treatment of a 68-year-old woman with myelofibrosis.
Pacritinib Added to NCCN Recommendation for Treatment in MPNsApril 17th 2022
The National Comprehensive Cancer Network has announced their recommendation for the use of pacritinib in the first line and second line setting for treating patients with myeloproliferative neoplasms.
Responses With Navitoclax/Ruxolitinib Appear to Modify Disease in Patients With MyelofibrosisApril 12th 2022
Changes like bone marrow fibrosis improvement and variant allele frequency reduction were seen with navitoclax plus ruxolitinib in patients with previously treated myelofibrosis in the REFINE study.
Raising Awareness for Polycythemia Vera is Key in Increasing Overall SurvivalMarch 18th 2022
In an interview with Targeted Oncology, Ghaith Abu-Zeinah, discussed the factors contributing to overall survival in patients with polycythemia vera and what is expected of future research.